Compare Adaptive Biotechnologies Corp (ADPT) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs British American Tobacco PLC — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while British American Tobacco PLC trades at $61.76 (market cap $132.11B). The key difference: British American Tobacco PLC is far larger — about 39.7× Adaptive Biotechnologies Corp's market cap, and British American Tobacco PLC pays a 5.4% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BTI | |
|---|---|---|
Market Cap | $3.33B | $132.11B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $66.70 |
52-Week Low | $10.24 | $47.93 |
Enterprise Value | $3.19B | $173.34B |
Dividend Yield | — | 5.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
British American Tobacco (BTI) trades at $61.80, up 0.05% on the day, with a bullish technical signal from moving averages and strong support at $61. The company shows robust profitability with a 30.32% net income margin and a 15.74% ROE, though revenue declined to $25.87B in 2024. Recent news highlights a major restructuring with 5,500 job cuts to drive cost savings and growth in non-traditional products like Velo nicotine pouches (Reuters, 2026-06-29).
BTI offers a compelling value with a P/E of 13.34 and a 5%+ dividend yield, supported by 66.7% analyst buy ratings. Key risks include regulatory pressures from the FDA's proposed oversight of foreign tobacco makers (Reuters, 2026-06-26) and volatile earnings, as seen in a 2023 net loss. The stock's outlook is positive for income-focused investors, balancing high margins with transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
